Bullish option flow detected in Biogen (BIIB) with 2,556 calls trading, 1.5x expected, and implied vol increasing over 1 point to 34.69%.

Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that ...

Experts at the 2025 Clinical Trial Supply New England conference will discuss strategies for optimising clinical supply ...

Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...

Biogen Canada Inc. is pleased to announce that Health Canada has approved SKYCLARYS™ (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in patients 16 years of age and older.2 This approval ...

Biogen Canada Inc. is pleased to announce that Health Canada has approved SKYCLARYStm (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in patients 16 years of age and older.2 This ...

As the only approved treatment to address disease progression, SKYCLARYS addresses a long-standing gap in the care of Canadians living with Friedreich's ataxia Friedreich's ...

TD Cowen analyst Phil Nadeau maintained a Hold rating on Xoma (XOMA – Research Report) yesterday. The company’s shares closed yesterday at ...

People who are 75 and older will compose 10% of the total population in the U.S. by 2030, representing a 7.5% increase from ...

If you work in the biotech industry, you might know the name Alex Denner. If not, his name probably doesn’t ring a bell.

Klick Health is kicking up its expansion in the Asia-Pacific region. | Klick Health is kicking up its expansion in the ...

A bill that could help Illinois residents access Alzheimer’s treatment is making its way through the House. House Bill 1360 ...